HELP
Helus Pharma Inc.

7,476
Mkt Cap
$303.86M
Volume
1.08M
52W High
$10.07
52W Low
$4.81
PE Ratio
-1.57
HELP Fundamentals
Price
$6.76
Prev Close
$6.09
Open
$6.40
50D MA
$7.04
Beta
0.78
Avg. Volume
448,815.75
EPS (Annual)
-$4.02
P/B
1.14
Rev/Employee
$0.00
Loading...
Loading...

About

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
50

Frequently Asked Questions

What is Market Cap of Helus Pharma Inc.?
What is the 52-week high for Helus Pharma Inc.?
What is the 52-week low for Helus Pharma Inc.?
What is Helus Pharma Inc. stock price today?
What was Helus Pharma Inc. stock price yesterday?
What is the PE ratio of Helus Pharma Inc.?
What is the Price-to-Book ratio of Helus Pharma Inc.?
What is the 50-day moving average of Helus Pharma Inc.?
How many employees does Helus Pharma Inc. have?

Latest HELP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.